The Akkermansia Company holds the only Akkermansia muciniphila strain approved as a novel food in Europe, using the pasteurised form the strongest human research tested.
Overview
The Akkermansia Company sells supplements built on Akkermansia muciniphila MucT, and its central claim is regulatory rather than promotional: it is the only Akkermansia muciniphila approved for use in foods in Europe. The company sought and obtained European Food Safety Authority approval for pasteurised Akkermansia muciniphila as a novel food ingredient, which is a substantial regulatory process rather than a label claim.
The pasteurisation detail is the technically interesting part, and it is counterintuitive. Most probiotic marketing treats live organisms as self-evidently superior, and every competitor selling Akkermansia invests in oxygen-free manufacturing and delayed-release capsules to keep a strictly anaerobic organism alive through production, shelf storage and stomach acid. The published human research on Akkermansia, however, tested pasteurised bacteria, and pasteurised Akkermansia performed at least as well as the live form. Using the pasteurised version therefore matches the evidence while eliminating the viability problem entirely.
Pricing in Europe runs around €29.95 through distributors such as Kala Health, with UK listings around £34.99 to £38, which compares favourably with US Akkermansia products. The realistic caveats are that EFSA approval establishes safety and novel food status rather than efficacy, that Akkermansia's human evidence for weight and metabolic outcomes remains preliminary, and that availability outside Europe is considerably more limited.
The Akkermansia Company at a Glance
| Detail | What The Akkermansia Company Publishes |
|---|---|
| Type of product | Akkermansia muciniphila supplement |
| Strain | Akkermansia muciniphila MucT |
| Regulatory status | The only Akkermansia approved by EFSA as a novel food in Europe |
| Form | Pasteurised rather than live |
| Why pasteurised matters | The strongest human trial tested the pasteurised form |
| European pricing | Around €29.95 |
| UK pricing | Around £34.99 to £38, with multi-buy options |
| Manufacturing | Produced in the Netherlands |
| Availability | Better in Europe than in the US |
| FDA evaluated | No, as with all dietary supplements |
What Is Actually in It
- Akkermansia muciniphila MucT, the strain used in published research
- The pasteurised form, matching what the human trial tested
- EFSA novel food approval, unique to this strain in Europe
- Production in the Netherlands
- A focused single-organism product rather than a blend
- Pricing from around €29.95 in Europe
Supplement or Medication?
A dietary supplement, and in Europe a regulated novel food ingredient. Akkermansia is a gut commensal associated with gut barrier integrity and metabolic markers. Any GLP-1 effect is indirect through the microbiome and considerably smaller than medication.
How You Buy It
Check availability in your country
European distribution is considerably better than US.
Buy direct or through a distributor
Kala Health and other European distributors stock it.
Take daily
A daily supplement rather than an as-needed product.
Give it months
Microbiome and metabolic changes are slow to assess.
Who It Is Sold To
- Adults wanting Akkermansia in the form the research tested
- No consultation or clinical assessment involved
- Pasteurised rather than live, so viability concerns do not apply
- Not appropriate as a substitute for prescribed obesity treatment
- European buyers have considerably better access than US buyers
- Speak to a clinician if you have a serious gastrointestinal condition
Clinical Oversight and Evidence
Clinical Oversight
None at the point of sale, though EFSA novel food approval means the strain has been through a formal European safety assessment, which is more regulatory scrutiny than almost anything else in this category has faced.
Evidence
Strong on strain provenance and safety, preliminary on outcome. The MucT strain is the one used in the published human research, and the pasteurised form is what that research tested. EFSA approval establishes safety and novel food status rather than efficacy. Akkermansia's human evidence for weight and metabolic outcomes remains at an early stage, and published reviews have urged caution about extrapolating from preclinical work.
Availability and Shipping
Where to Buy
Direct from The Akkermansia Company and through European distributors including Kala Health. Availability outside Europe is more limited.
Shipping
European distribution primarily. As a pasteurised product it has fewer handling constraints than live probiotics.
What You Get
- The only EFSA-approved Akkermansia strain in Europe
- Published information on the strain and its regulatory status
- Production in the Netherlands
- European distributor network
- A form that matches the published research
- No clinical support, monitoring or personalisation
Pricing
Competitive by Akkermansia standards, particularly against US products using live strains that require expensive manufacturing.
| Product or Plan | Published Price | What It Covers |
|---|---|---|
| European pricing | Around €29.95 | Through distributors such as Kala Health |
| UK pricing | Around £34.99 to £38 | With multi-buy options available |
| Comparable US products | Higher | Live-strain products require costlier manufacturing |
| Subscription | Varies by distributor | Depends on where you buy |
Pricing reflects what The Akkermansia Company published at the time of review and can change without notice. Confirm current pricing directly with the seller before buying.
Membership Fees
None. Ordinary retail purchasing through direct and distributor channels.
Annual Cost
Roughly €360 a year at €29.95 monthly, which compares well with US Akkermansia products.
Cancellation and Refund Policy
Cancellation
Depends on the distributor used.
Refunds
Varies by distributor and jurisdiction. European consumer protection rules apply within the EU.
Insurance, HSA and FSA
Insurance
Not applicable to a dietary supplement.
HSA / FSA
Generally not eligible, and largely irrelevant given that distribution is primarily European.
For a fuller explanation of how these accounts work with GLP-1 care, see our GLP-1 insurance, HSA and FSA guide.
Who The Akkermansia Company May Be Best For
- You want the Akkermansia strain used in published research
- You are in Europe or the UK where availability is good
- You want the pasteurised form the human trial actually tested
- You value EFSA novel food approval as a safety signal
- You prefer one organism to a nine-ingredient blend
- You accept the outcome evidence is still developing
- US availability lags Europe considerably
- EFSA approval addresses safety rather than efficacy
- Akkermansia's human weight evidence remains preliminary
- A narrow range built on a single organism
- No trial on the finished consumer product
- Microbiome effects take months to assess
Alternatives to Consider
Designs for Health Akkermansia Pro
A live-strain US alternative with published colony counts.
Pendulum GLP-1 Probiotic
The best-known US Akkermansia specialist.
Seed DS-01 Daily Synbiotic
A broader 24-strain product with its own trial data.
Vitamatic GLP-1 Support
Claims Akkermansia far more cheaply, with no colony count published.
You can also compare the whole field in our best GLP-1 supplements and GLP-1 supplement evidence review roundups.
Frequently Asked Questions
Why does pasteurised Akkermansia matter?
Because the strongest published human research on Akkermansia tested the pasteurised form, and it performed at least as well as the live version. Using pasteurised bacteria therefore matches the evidence while avoiding the viability problems that make live anaerobic Akkermansia so difficult to deliver.
What does EFSA approval mean?
The European Food Safety Authority approved pasteurised Akkermansia muciniphila as a novel food ingredient, which is a formal safety assessment. It establishes safety and legal status in Europe rather than proving efficacy.
Is it available in the US?
Availability outside Europe is considerably more limited. European and UK buyers have much better access, with pricing around €29.95 or £34.99 to £38.
What is MucT?
The specific Akkermansia muciniphila strain used in the published research and in this company's products.
Does Akkermansia cause weight loss?
The human evidence remains preliminary. There is genuinely interesting research on gut barrier integrity and insulin sensitivity, and published reviews have urged caution about extrapolating from the preclinical work.
How does it compare to live Akkermansia products?
Live products require oxygen-free manufacturing and delayed release to keep a strictly anaerobic organism viable, which is expensive. The pasteurised approach avoids that problem while matching what the research tested.
Is it FDA approved?
No. It is a dietary supplement, so it does not require FDA approval before marketing and its claims have not been evaluated by the FDA.